Claims

1. Use of a dopamine agonist and an alpha-2-adrenergic agonist ~~a chemical composition~~ in the manufacture of a medicament for the treatment of hot flashes, wherein the dopamine agonist is capable of binding to one or more of D_2, D_3, or D_4 dopamine receptors or is capable of binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor, wherein:

(a) the dopamine agonist that is capable of binding to one or more of the D_2, D_3, or D_4 receptors is Ropinirole, and the alpha-2-adrenergic agonist is Clonidine,

(b) the dopamine agonist that is capable of binding to one or more of the D_2, D_3, or D_4 receptors is Pramipexole, and the alpha-2-adrenergic agonist is Tizanidine,

(c) the dopamine agonist that is capable of binding to one or more of the D_2, D_3, or D_4 receptors is Pramipexole, and the alpha-2-adrenergic agonist is Clonidine,

(d) the dopamine agonist -that is capable of binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor is Venlafaxine, and the alpha-2-adrenergic agonist is Tizanidine,

(e) the dopamine agonist -that is capable of binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor is Paroxetine, and the alpha-2-adrenergic agonist is Tizanidine,

(f) the dopamine agonist -that is capable of binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor is Gabapentin and the alpha-2-adrenergic agonist is Tizanidine,

(g) the dopamine agonist -that is capable of binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor is Pregabilin, and the alpha-2-adrenergic agonist is Tizanidine, or

(h) the dopamine agonist –that is capable of binding to one or more of the D_2, D_3, or D_4 receptors is Rotigotine or Piribidel, and the alpha-2-adrenergic agonist is Tizanidine or Clonidine.

~~the chemical composition comprising a dopamine agonist capable of binding to D2, D3, or D4 dopamine receptors.~~

~~2. The use of a chemical composition as set forth in claim 1 wherein the medicament is in a form for administration selected from the group consisting a pill, an oral liquid form, an intravenous liquid form, a transdermal patch, and an inhalable composition.~~

~~3. Use of a chemical composition in the manufacture of a medicament for the treatment of hot flashes, the composition comprising a dopamine agonist capable of binding to D2, D3, or D4 dopamine receptors,~~

~~wherein the medicament is to be administered to a person experiencing hot flashes in combination with a further composition that comprises an alpha-2-adrenergic agonist capable of binding to alpha-2-adrenergic receptor.~~

~~4. The use of a chemical composition as set forth in claim 3, wherein the medicament is in a form for administration selected from the group consisting a pill, an oral liquid form, an intravenous liquid form, a transdermal patch, and an inhalable composition, and~~
~~the further chemical composition that comprises an alpha-2-adrenergic agonist is to be provided in a form for administration selected from the group consisting a pill, an oral liquid form, an intravenous liquid form, a transdermal patch, and an inhalable composition.~~

~~5. Use of a chemical composition in the manufacture of a medicament for the treatment of hot flashes, the chemical composition comprising an alpha-2-adrenergic agonist capable of binding to alpha-2-adrenergic receptor,~~

~~wherein the medicament is to be administered to a person experiencing hot flashes in combination with a further composition that comprises a dopamine agonist capable of binding to D2, D3, or D4 dopamine receptors.~~

~~6. The use of a chemical composition as set forth in claim 5, wherein the medicament is in a form for administration selected from the group consisting of a pill, an oral liquid form, an intravenous liquid form, a transdermal patch, and an inhalable composition, and~~

~~the further composition that comprises a dopamine agonist is to be provided in a form for administration selected from the group consisting a pill, an oral liquid form, an intravenous liquid form, a transdermal patch, and an inhalable composition.~~

~~7. Use of a chemical composition in the manufacture of a medicament for the treatment of hot flashes, the composition comprising a dopamine agonist capable of binding to D2, D3, or D4 dopamine receptors and an alpha-2-adrenergic agonist capable of binding to alpha-2-adrenergic receptor.~~

~~8~~2. The use ~~of a chemical composition~~ as set forth in claim ~~1~~7, wherein the medicament is in a form for administration selected from the group consisting of a pill, an oral liquid form, an intravenous liquid form, a transdermal patch, and an inhalable composition.

~~9~~3. A composition suitable for treatment of hot flashes, comprising a dopamine agonist and an alpha-2-adreneric agonist, wherein the dopamine agonist is capable of binding to one or more of D_2, D_3, or D_4 dopamine receptors or binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor, wherein:
(a) the dopamine agonist that is capable of binding to one or more of the D_2, D_3, or D_4 dopamine receptors is Ropinirole and the alpha-2-adreneric agonist is Clonidine,

(b) the dopamine agonist that is capable of binding to one or more of the D_2, D_3, or D_4 dopamine receptors is Pramipexole and the alpha-2-adreneric agonist is Tizanidine,
(c) the dopamine agonist that is capable of binding to one or more of the D_2, D_3, or D_4 dopamine receptors is Pramipexole and the alpha-2-adreneric agonist is Clonidine,
(d) the dopamine agonist that is capable of binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor is Venlafaxine and the alpha-2-adreneric agonist is Tizanidine,
(e) the dopamine agonist that is capable of binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor is Paroxetine and the alpha-2-adreneric agonist is Tizanidine,
(f) the dopamine agonist that is capable of binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor is Gabapentin and the alpha-2-adreneric agonist is Tizanidine,
(g) the dopamine agonist that is capable of binding to a heterodimer comprising a D_2, D_3, or D_4 dopamine receptor is Pregabilin and the alpha-2-adreneric agonist is Tizanidine, or
(h) the dopamine agonist that is capable of binding to one or more of the D_2, D_3, or D_4 receptors is Rotigotine or Piribidel, and the alpha-2-adrenergic agonist is Tizanidine or Clonidine.
~~a substance that is a dopamine agonist capable of binding to D_2, D_3, or D_4 dopamine receptors, and a substance that is an alpha-2-adreneric agonist.~~

~~10~~4. A composition as set forth in claim ~~9~~ 3 comprising a form which is capable of administration to an individual as a pill.

~~11~~5. A composition as set forth in claim ~~10~~ 4 comprising a form which is capable of administration to an individual as a pill and wherein the dopamine agonist and the alpha-2-adrenergic agonist are separately placed within the pill.

~~12~~6. A composition as set forth in claim ~~10~~ 4 comprising a form which is capable of administration to an individual as a pill and wherein the dopamine agonist and the alpha-2-adrenergic agonist are combined within the pill.

~~13~~7. A composition as set forth in claim ~~9~~ 3 comprising a form which is capable of administration to an individual orally as a liquid.

~~14~~8. A composition as set forth in claim ~~9~~ 3 comprising a form which is capable of administration to an individual intravenously as a liquid.

~~15~~9. A composition as set forth in claim ~~9~~ 3 comprising a form which is capable of administration to an individual by inhalation.

~~16. A composition as set forth in claim 9 wherein the substance that is a dopamine agonist capable of binding to D_2, D_3, or D_4 dopamine receptors is selected from the group consisting of ropinirole, rotigitine, pramipexole, piribedil, venlafaxine, paroxetine, gabapentin, and pregabilin and the substance that is an alpha-2-adreneric agonist is selected from the group consisting of tizanidine and clonidine.~~